Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | EP300 | Q09472 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 2/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9584645 | 0.95 | EP300 (0.52) | FGFR1EP300ADORA2ACYP3A4CYP2D6 | |
| SCHEMBL9584354 | 0.95 | EP300 (0.52) | FGFR1EP300ADORA2ACYP3A4CYP2D6 | |
| SCHEMBL9583468 | 0.86 | PDE3A (0.47) | FGFR1EP300CYP3A4ALDH1A1PRKCA | |
| SCHEMBL9583885 | 0.86 | CYP1A2 (0.50) | FGFR1EP300ALDH1A1PRKCAPRKCE | |
| SCHEMBL10818140 | 0.83 | ADORA2A (0.50) | ADORA2ACYP3A4ALDH1A1ADCY5PDE3A | |
| SCHEMBL9583644 | 0.83 | CYP1A2 (0.45) | FGFR1CYP3A4CYP2D6ALDH1A1PRKCA | |
| SCHEMBL9583142 | 0.83 | CDK1 (0.46) | EP300CYP3A4ALDH1A1PRKCAPRKCE | |
| SCHEMBL9583536 | 0.83 | CDK1 (0.46) | EP300CYP3A4ALDH1A1PRKCAPRKCE | |
| SCHEMBL9583245 | 0.83 | CDK1 (0.46) | EP300CYP3A4ALDH1A1PRKCAPRKCE | |
| SCHEMBL9583458 | 0.83 | CDK1 (0.46) | EP300CYP3A4ALDH1A1PRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5250535-A | Herpes virus; nontoxic; side effect reduction; humans and veterinary medicine | SYNTEX INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-4803271-A | Process for preparing guanine derivatives | SYNTEX (U.S.A.) INC. (US) | 1989-02-07 | — | — | US | disclosed |
| US-4612314-A | Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1986-09-16 | — | — | US | disclosed |
| EP-0085424-A2 | Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1983-08-10 | — | — | EP | disclosed |